Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $189.0M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Nuvectis Pharma, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 0 | 8 | +8 |
| Shares | 0 | 628.1K | +628.1K |
| Value | $0 | $4.65M | +$4.65M |
New holders (8)
Institutions that held Nuvectis Pharma, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ronit Capital LLP | 550,000 | $4.08M | 5.45% |
| Millennium Management LLC | 42,160 | $312.0K | 0.00% |
| Geode Capital Management, LLC | 14,822 | $109.0K | 0.00% |
| Virtu Financial LLC | 11,365 | $84.0K | 0.01% |
| BlackRock Inc. | 7,872 | $59.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,750 | $13.0K | 0.00% |
| UBS Group AG | 141 | $1.00K | 0.00% |
| Wells Fargo & Company | 20 | $0 | 0.00% |
Sold out (0)
Institutions that held Nuvectis Pharma, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
None.